Realizing the of Potential “Bionic” Nanoparticles for Delivery to Live Cells

Abcam and SomaServe, a Pharma service and specialist reagent business exploiting PolyNaut® Technology, have announced a partnership to commercialize the cell delivery potential of the polymer-based “bionic”’ nanoparticles, which can carry a range of payloads directly to live cells.

The collaboration will initially focus on the development and global commercialization of a suite of CelLuminate dyes, specifically created to revolutionize live cell imaging by enabling cells to remain functional and viable for up to 14 days. This reduction in toxicity is designed to give users the ability to thoroughly probe and analyze their cells, enabling them to achieve deeper insights and advance their understanding.

Beyond the aim of improving and enhancing live cell imaging, the team will work together to expand the delivery and assay options of the platform, including optimizing its potential in combination with antibodies and other technologies. In addition to the commercial partnership, Abcam has invested in SomaServe’s seed round to help accelerate the development of an innovative market-leading platform for research, diagnostic and therapeutic applications.